For research and educational purposes only. Not medical advice.
Tesamorelin and visceral fat: what the labeled trial evidence supports, and what it does not
Tesamorelin is one of the few peptides with a clear, narrow FDA label and substantial human trial evidence for visceral fat reduction. The off-label conversa…
Category: Peptides. 8 min read. Published 2026-04-27.
The labeled indication, in plain language
Tesamorelin (Egrifta WR) is FDA-approved for the reduction of excess abdominal fat in adult patients with HIV-associated lipodystrophy. It is a synthetic analog of growth-hormone-releasing hormone (GHRH) and acts on the pituitary to increase endogenous GH and IGF-1 secretion. The DailyMed labeling spells out the indication, dosing, monitoring expectations, and contraindications .
The pivotal trials that supported approval enrolled HIV patients with visible truncal lipohypertrophy. Results showed reductions in visceral adipose tissue (VAT) measured by CT, with the effect typically attenuating after discontinuation .
What the trials actually showed
- Reductions in CT-measured visceral adipose tissue (VAT) on the order of 15 percent over 26 weeks in the labeled population.
- Modest improvements in lipid panels and liver fat (NAFLD-related markers) in subgroup analyses.
- Reversal of effect after discontinuation; the data suggest tesamorelin produces ongoing rather than durable change without continued therapy.
- Adverse effects: injection-site reactions, arthralgia, peripheral edema, and the IGF-1 elevation that comes with any GH-axis modulation.
The off-label conversation
Outside the HIV-lipodystrophy population, tesamorelin has been studied in smaller trials for general visceral adiposity, NAFLD, and as a research probe for GH-axis activation. Some of those studies show signals consistent with the labeled population, but the trial sizes are smaller and the populations have different baseline metabolic posture .
The honest framing is that tesamorelin has clear label-grade evidence in a specific population and a thinner literature elsewhere. Visceral fat is also moved by training, sleep, alcohol intake, and energy balance, all of which are upstream of any pharmacologic intervention.
Monitoring and clinical cautions
Tesamorelin elevates IGF-1 by design. The labeling identifies monitoring expectations and contraindications: known hypersensitivity, pregnancy, disrupted hypothalamic-pituitary axis, active malignancy. Athletes subject to anti-doping rules should note that GH-axis-active compounds sit under WADA category S2 .